These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 35428853)

  • 21. Bayesian Inference of State-Level COVID-19 Basic Reproduction Numbers across the United States.
    Mallela A; Neumann J; Miller EF; Chen Y; Posner RG; Lin YT; Hlavacek WS
    medRxiv; 2021 Sep; ():. PubMed ID: 34611664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland, Australia.
    Adegbija O; Walker J; Smoll N; Khan A; Graham J; Khandaker G
    Commun Dis Intell (2018); 2021 Feb; 45():. PubMed ID: 33632091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2.
    Chun JY; Jeong H; Kim Y
    JAMA Netw Open; 2022 Mar; 5(3):e223064. PubMed ID: 35302625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of COVID-19 in Amazonia: A history of government denialism and the risk of a third wave.
    Ferrante L; Duczmal LH; Capanema E; Steinmetz WAC; Almeida ACL; Leão J; Vassão RC; Fearnside PM; Tupinambás U
    Prev Med Rep; 2022 Apr; 26():101752. PubMed ID: 35242505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination as an alternative to non-drug interventions to prevent local resurgence of COVID-19.
    Pan J; Zhu W; Tian J; Liu Z; Xu A; Yao Y; Wang W
    Infect Dis Poverty; 2022 Mar; 11(1):36. PubMed ID: 35346382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling SARS-CoV-2 disease progression in Australia and New Zealand: an account of an agent-based approach to support public health decision-making.
    Thompson J; McClure R; Blakely T; Wilson N; Baker MG; Wijnands JS; De Sa TH; Nice K; Cruz C; Stevenson M
    Aust N Z J Public Health; 2022 Jun; 46(3):292-303. PubMed ID: 35238437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating COVID Risk During a Period of Pandemic Decline.
    Inglis TJJ; McFadden B; Macali A
    Front Public Health; 2021; 9():744819. PubMed ID: 34976916
    [No Abstract]   [Full Text] [Related]  

  • 29. Challenges in the control of COVID-19 outbreaks caused by the delta variant during periods of low humidity: an observational study in Sydney, Australia.
    Ward MP; Liu Y; Xiao S; Zhang Z
    Infect Dis Poverty; 2021 Dec; 10(1):139. PubMed ID: 34937575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical and agent-based modelling of the transmissibility of different SARS-CoV-2 variants in England and impact of different interventions.
    Panovska-Griffiths J; Swallow B; Hinch R; Cohen J; Rosenfeld K; Stuart RM; Ferretti L; Di Lauro F; Wymant C; Izzo A; Waites W; Viner R; Bonell C; Fraser C; Klein D; Kerr CC;
    Philos Trans A Math Phys Eng Sci; 2022 Oct; 380(2233):20210315. PubMed ID: 35965458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical timing and extent of public health interventions to control outbreaks dominated by SARS-CoV-2 variants in Australia: a mathematical modelling study.
    Zou Z; Fairley CK; Shen M; Scott N; Xu X; Li Z; Li R; Zhuang G; Zhang L
    Int J Infect Dis; 2022 Feb; 115():154-165. PubMed ID: 34800688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System - California, March-July 2021.
    Malden DE; Bruxvoort KJ; Tseng HF; Ackerson B; Choi SK; Florea A; Tubert J; Takhar H; Aragones M; Hong V; Talarico CA; McLaughlin JM; Qian L; Tartof SY
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(40):1415-1419. PubMed ID: 34618801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study.
    Corrao G; Franchi M; Rea F; Cereda D; Barone A; Borriello CR; Della Valle PG; Ercolanoni M; Fortino I; Jara J; Leoni O; Mazziotta F; Pierini E; Preziosi G; Tirani M; Galli M; Bertolaso G; Pavesi G; Bortolan F
    BMC Med; 2022 Feb; 20(1):52. PubMed ID: 35130877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of vaccine prioritization strategies on mitigating COVID-19: an agent-based simulation study using an urban region in the United States.
    Tatapudi H; Das R; Das TK
    BMC Med Res Methodol; 2021 Dec; 21(1):272. PubMed ID: 34865617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmission of SARS-CoV-2 Delta variant from an infected aircrew member on a short-haul domestic flight, Australia 2021.
    Williamson KM; Butler M; Elton B; Taylor J; Islam F; Douglas MP; Kirk MD; Durrheim DN
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36448584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventing a cluster from becoming a new wave in settings with zero community COVID-19 cases.
    Abeysuriya RG; Delport D; Stuart RM; Sacks-Davis R; Kerr CC; Mistry D; Klein DJ; Hellard M; Scott N
    BMC Infect Dis; 2022 Mar; 22(1):232. PubMed ID: 35255823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 in low-tolerance border quarantine systems: Impact of the Delta variant of SARS-CoV-2.
    Zachreson C; Shearer FM; Price DJ; Lydeamore MJ; McVernon J; McCaw J; Geard N
    Sci Adv; 2022 Apr; 8(14):eabm3624. PubMed ID: 35394833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between Population Density and COVID-19 Cases during the Third Wave in Malaysia: Effect of the Delta Variant.
    Md Iderus NH; Lakha Singh SS; Mohd Ghazali S; Yoon Ling C; Cia Vei T; Md Zamri ASS; Ahmad Jaafar N; Ruslan Q; Ahmad Jaghfar NH; Gill BS
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What vaccination rate(s) minimize total societal costs after 'opening up' to COVID-19? Age-structured SIRM results for the Delta variant in Australia (New South Wales, Victoria and Western Australia).
    Chu L; Grafton RQ; Kompas T
    PLOS Glob Public Health; 2022; 2(6):e0000499. PubMed ID: 36962399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.